Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 24, Issue 1, 1999, Pages 5-11

  Poonkuzhali, B ^a   Srivastava, A ^a   Quernin, M H ^b   Dennison, D ^a   Aigrain, E J ^b   Kanagasabapathy, A S ^a   Krishnamoorthy, R ^b   Chandy, M ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Bone marrow transplantation; Busulphan; Pharmacokinetics; Thalassaemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0032792198     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701814     Document Type: Article

References (29)

1. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute non-lymphocytic leukaemia after treatment with busulphan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
2. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukaemia with allogeneic bone marrow transplantation following preparation with BU-CY2. Blood 1991; 78: 838-843.
3. Parkman R, Rappeport JM, Hellman S et al. Busulphan and total body irradiation as anti-haematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation. Blood 1984; 64: 852-857.
4. Shaw PJ, Hugh-Jones K, Hobbs JR et al. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1: 193-200.
5. Porcellini A, Manna A, Moretti L et al. Busulphan and cyclophosphamide as conditioning regimen for autologous bone marrow transplantation in acute lymphoblastic leukaemia. Bone Marrow Transplant 1989; 4: 331-333.
6. Lucarelli G, Giardini C and Baronciani D. Bone marrow transplantation in thalassaemia. Semin Hematol 1995; 32: 297-303.
7. 2 the appropriate dosage of busulphan in children undergoing bone marrow transplantation? Blood 1993; 79: 2475-2479.
8. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulphan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
9. Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-1034.
10. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulphan pharmacokinetics using a single daily high dose regimen in children with acute leukaemia. Blood 1994; 84: 2357-2362.
11. Yeager AM, Wagner JE, Graham ML et al. Optimization of busulphan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
12. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high dose oral busulphan to the outcome of allogeneic bone marrow transplantation in children with thalassaemia. Blood 1996; 88 (Suppl. 1): 457a.
13. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high dose oral busulphan to the outcome of allogeneic BMT in children with thalassaemia. Bone Marrow Transplant 1997; 20: 915-920.
14. Quernin MH, Poonkuzhali B, Montes C et al. Quantification of busulphan in plasma by gas chromatography-mass spectrometry. J Chromatogr 1998; 709: 47-56.
15. Heinzel G, Woloszezak R, Thoman P. Pharmacokinetic Pharmacodynamic Data Analysis System for the PC. Gustav Fischer: Stuttgart, Germany, 1993.
16. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
17. Jones RJ, Lee KSK, Beschorner WE et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
18. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-112.
19. Ehrsson H, Hassan M. Determination of busulphan in plasma by gas chromatography with selected ion monitoring. J Pharm Sci 1983; 72: 1203-1205.
20. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity in relation to busulphan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
21. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
22. Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high dose busulphan in children. Cancer Chemother Pharmacol 1989; 24: 386-390.
23. Grochow LB, Krivit W, Withley CB, Blazar B. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
24. Hassan M, Fasth A, Gerritsen B et al. Busulfan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843-850.
25. Fitzsimmons W, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulphan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990; 27: 226-228.
26. Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.
27. Dix SP, Wingard JR, Mullins RE et al. Association of busulphan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
28. Vassal G, Koscielny S24, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247-253.
29. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassaemia. New Engl J Med 1990; 332: 417-421.